Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived virus-like particles.
Foreign protein sequences presented on hamster polyomavirus (HaPyV) major capsid protein VP1-derived virus-like particles (VLPs) have been demonstrated to be highly immunogenic. The current study was aimed to evaluate VP1-derived chimeric VLPs as tools for hybridoma technology to generate monoclonal antibodies (mAbs) of desired specificity. Chimeric VLPs containing inserts of different size and origin were used as immunogens. Chimeric VLPs carrying a 9 amino acid (aa)-long cytotoxic T-cell epitope (STAPPVHNV) of human mucin 1 (MUC1) elicited a strong epitope-specific humoral immune response in mice and promoted the production of MUC1-specific mAbs. From a total of seven mAbs of IgG isotype generated against the chimeric VLPs, two mAbs were directed against the MUC1 epitope and five mAbs against the VP1-carrier. Two out of five anti-VP1 mAbs recognized epitopes located at the previously defined insertion site #2 (aa 223/224), which confirms its surface-exposed localization. Chimeric VLPs carrying a 120-aa long sequence of Puumala hantavirus (PUUV) nucleocapsid protein (NP) promoted the generation of five mAbs of IgG isotype specific to PUUV NP. All mAbs recognized the full-length NP of different PUUV strains. In contrast, no VP1-specific mAbs were obtained. The ability of chimeric VLPs to activate antigen-presenting cells was evaluated by studying the uptake of chimeric VLPs by murine spleen cell-derived dendritic cells (DCs). Efficient uptake of VLPs and activation of murine DCs were demonstrated, which may represent the basis of the strong immunogenicity of chimeric VLPs. In conclusion, chimeric VLPs effectively stimulated the production of IgG antibodies specific for foreign epitopes presented at surface-exposed regions. Thus, chimeric HaPyV VP1-derived VLPs represent efficient immunogens for hybridoma technology and provide a promising alternative to chemical coupling of synthetic peptides to carrier proteins.
Zvirbliene
A
A
Institute of Biotechnology, V. Graiciuno 8, LT-02241 Vilnius, Lithuania. azvirb@ibt.lt
Samonskyte
L
L
Gedvilaite
A
A
Voronkova
T
T
Ulrich
R
R
Sasnauskas
K
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000096:biosynthesis* / Q000276:immunology*; D000918:Antibody Specificity; D000951:Antigens, Neoplasm; D015153:Blotting, Western; D036022:Capsid Proteins / Q000235:genetics* / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D018604:Epitope Mapping; D000939:Epitopes / Q000276:immunology; D006825:Hybridomas / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018396:Mucin-1; D009077:Mucins / Q000276:immunology; D019590:Nucleocapsid Proteins / Q000235:genetics; D011120:Polyomavirus / Q000235:genetics*; D029262:Puumala virus / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis / Q000276:immunology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D036022:Capsid Proteins; D000939:Epitopes; D007074:Immunoglobulin G; C060192:MUC1 protein, human; D018396:Mucin-1; D009077:Mucins; D019590:Nucleocapsid Proteins; D011993:Recombinant Fusion Proteins; C062481:VP1 protein, polyomavirus